Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in Patients with Advanced and Recurrent Cervical Cancer Regardless of Bevacizumab Use By Ogkologos - November 25, 2024 891 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the subgroup analysis of the KEYNOTE-826 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR FDA Grants Traditional Approval to Selpercatinib for RET Fusion-positive Thyroid Cancer July 2, 2024 ESMO Targeted Anticancer Therapies Congress 2025, Paris, France, 3-5 March February 24, 2025 Targeted Drug Trio Improves Survival in Colorectal Cancer with BRAF Mutations November 13, 2019 Cancer clinical trials – learning lessons from the COVID-19 pandemic May 19, 2021 Load more HOT NEWS Pharmacokinetic and Pharmacodynamic Interactions Between Anticancer and Antiviral Drugs Announcing ‘Cancer Revolution’ – a world-first exhibition to engage people with... Your NCI: Top Priorities from AACR 2026 Adjuvant Pembrolizumab Plus Chemotherapy Improves DFS in Patients with Newly-Diagnosed, High-Risk...
